🇺🇸 FDA
Pipeline program

Saruparib, ZYTIGA 500 mg film-coated tablets, Erleada 60 mg film-coated tablets, Saruparib, Xtandi - 40 mg soft capsules, Prednisone Mylan Pharma 5 mg compresse, NUBEQA 300 mg film-coated tablets, Saruparib

D9720C00003

Phase 2 small_molecule active

Quick answer

Saruparib, ZYTIGA 500 mg film-coated tablets, Erleada 60 mg film-coated tablets, Saruparib, Xtandi - 40 mg soft capsules, Prednisone Mylan Pharma 5 mg compresse, NUBEQA 300 mg film-coated tablets, Saruparib for Metastatic Prostate Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Metastatic Prostate Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials